Promomed Group expects demand for its overweight and obesity drug to grow tenfold this year. The company introduced Velgia in early October 2024, and by the end of the year sales had already reached ₽1 billion.

Promomed's revenue for 2024 amounted to ₽21.1 billion, up 33% year-on-year. Share of revenue from sales of innovative products increased by 10 p.p. to 58%. Volume of export sales increased by 46%.

Promomed's sales in January 2025 increased by 28% year-on-year. Share of revenue from sales of innovative products reached 70%, which is 26 p.p. higher than a year earlier. Notable contribution to the increase in sales was made by the launch of the innovative drug Velgia®, which accounted for 42% of sales in the Endocrinology segment. Shipments of such produ...

Promomed has registered a drug for reducing excess weight and treating obesity, Tirzetta. It is the first Russian competitor of the well-known and not available in Russia drug Mounjaro. According to Strategy Partners' research, the Russian market for drugs to combat overweight and diabetes will grow by almost 80% to reach ₽17 billion in 2025.